���发背景与监管地位 — Hands-On Walkthrough

By Editorial Desk · published 2026-05-28 · last reviewed 2026-06-29 · Info

Everything below concerns Semax. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-06-29. Numbers and descriptions here follow the published literature rather than marketing material.

研发背景与监管地位

Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。

Chemical Identity and Research Background

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.

Semax at a glance

Semax Background and Molecular Structure

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.

The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.

Related pages on this site

• Lightweight collection
• Adaptive archive
• Clear overview
• Sustainable checklist
• Smart archive
• Standard comparison
• Scheduled archive
• Seasonal comparison

Semax Origin and Molecular Structure

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.

The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.

Semax Structure and Research Background

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Semax Background And Mechanism

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.

The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.

Supporting material

Misuse by injection or use in the nose still occurs, and more recently the efficacy of naloxone in preventing misuse by injection has been brought into question and preparations including naloxone could even be less safe than preparations containing solely buprenorphine. Rates of misuse in the U.S. appear to be lower than with other opioids. The combination formulation was approved for medical use in the US in 2002, and in the European Union in 2017. A generic version was approved in the US in 2018. In 2019, it was the 272nd most commonly prescribed medication in the US, with more than 1 million prescriptions.

An electrophilic cyclization occurs in step 5, and an intramolecular proton transfer attacks the taxenyl cation (step 6). This forms the fused ring structure intermediate known as taxadiene. Taxadiene then undergoes a series of 10 oxidations via NADPH, forming the intermediate taxadiene-5α-acetoxy-10β-ol (multiple steps later in the figure). A series of hydroxylations and esterficiations occur, forming the intermediate 10-deacetyl-baccatin III, which undergoes a further series of esterifications and a side-chain hydroxylation. This finally yields the product paclitaxel.

== Clinical significance == Leukotrienes, which require the FLAP protein to be synthesized, have an established pathological role in allergic and respiratory diseases. Animal and human genetic evidence suggests they may also have an important role in atherosclerosis, myocardial infarction, and stroke. The structure of FLAP provides a tool for the development of novel therapies for respiratory and cardiovascular diseases and for the design of focused experiments to probe the cell biology of FLAP and its role in leukotriene biosynthesis.

Sources: en.wikipedia.org

Notes from published material

At the age of 16, Tolkien met Edith Mary Bratt, who was three years his senior, when he and his brother Hilary moved into the boarding house where she lived in Duchess Road, Edgbaston. According to Humphrey Carpenter, "Edith and Ronald took to frequenting Birmingham teashops, especially one which had a balcony overlooking the pavement. There they would sit and throw sugarlumps into the hats of passers-by, moving to the next table when the sugar bowl was empty. ... With two people of their personalities and in their position, romance was bound to flourish. Both were orphans in need of affection, and they found that they could give it to each other. During the summer of 1909, they decided that they were in love." His guardian, Father Morgan, considered it "altogether unfortunate" that his surrogate son was romantically involved with an older, Protestant woman; Tolkien wrote that the combined tensions contributed to his having "muffed [his] exams". Morgan prohibited him from meeting, talking to, or even corresponding with Edith until he was 21. Tolkien obeyed this prohibition to the letter, with one notable early exception, over which Father Morgan threatened to cut short his university career if he did not stop. On the evening of his 21st birthday Tolkien wrote to Edith, who was living with a family friend named C. H. Jessop in Cheltenham. He declared that he had never ceased to love her, and asked her to marry him. Edith replied that she had already accepted the proposal of George Field, the brother of one of her closest school friends.

Alexander George Ogston FAA FRS (30 January 1911 – 29 June 1996) was a British biochemist who specialised in the thermodynamics of biological systems. He was a grandson of Sir Alexander Ogston, a Scottish surgeon who discovered Staphylococcus.

Colombia has a vibrant collage of talent that touches a full spectrum of rhythms. It is known as the land of a thousand rhythms, at around 1,024 folk rhythms. Musicians, composers, music producers and singers from Colombia are recognized internationally such as Shakira, Juanes, Carlos Vives and others. Colombian music blends European-influenced guitar and song structure with large gaita flutes and percussion instruments from the indigenous population, while its percussion structure and dance forms come from Africa. Colombia has a diverse and dynamic musical environment.

Sources: en.wikipedia.org

Further detail

Philip wrote a contract giving Tessa half of all the rights to the novel, which stated that Tessa "participated to a great extent in writing the outline and novel A Scanner Darkly with me, and I owe her one half of all income derived from it". There was also the challenge of transmuting the events into "science fiction", as Dick felt that he could not sell a mainstream or literary novel after several previous failures. Providing invaluable aid in this field was Judy-Lynn del Rey, head of Ballantine Books' SF division, which had optioned the book. Del Rey suggested the timeline change to 1994 and emphasized the more futuristic elements of the novel, such as the "scramble suit" employed by Fred (which, incidentally, emerged from one of the mystical experiences). Yet much of the dialogue spoken by the characters used hippie slang, dating the events of the novel to their "true" time-frame of 1970–72. Upon its publication in 1977, A Scanner Darkly was hailed by ALA Booklist as "his best yet!" Brian Aldiss lauded it as "the best book of the year", while Robert Silverberg praised the novel as "a masterpiece of sorts, full of demonic intensity", but concluded that "it happens also not to be a very successful novel... a failure, but a stunning failure". Spider Robinson panned the novel as "sometimes fascinating, sometimes hilarious, [but] usually deadly boring". Sales were typical for the SF genre in America, but hardcover editions were issued in Europe, where all of Dick's works were warmly received.

Wallace's patent application was granted in 1953, and after improvements to the aperture and the introduction of a mercury manometer to provide precise control over sample size, the brothers founded Coulter Electronics Inc. in 1958 to market their instruments. The Coulter counter was initially designed for counting red blood cells, but with later modifications it proved effective for counting white blood cells. Coulter counters were widely adopted by medical laboratories. The first analyzer able to produce multiple cell counts simultaneously was the Technicon SMA 4A−7A, released in 1965. It achieved this by partitioning blood samples into two channels: one for counting red and white blood cells and one for measuring hemoglobin. However, the instrument was unreliable and difficult to maintain. In 1968, the Coulter Model S analyzer was released and gained widespread use. Similarly to the Technicon instrument, it used two different reaction chambers, one of which was used for the red cell count, and one of which was used for the white blood cell count and hemoglobin determination. The Model S also determined the mean cell volume using impedance measurements, which allowed the red blood cell indices and hematocrit to be derived. Automated platelet counts were introduced in 1970 with Technicon's Hemalog-8 instrument and were adopted by Coulter's S Plus series analyzers in 1980. After basic cell counting had been automated, the white blood cell differential remained a challenge.

The Boc group can be added to the amine under aqueous conditions using di-tert-butyl dicarbonate in the presence of a base such as sodium bicarbonate. Protection of the amine can also be accomplished in acetonitrile solution using 4-dimethylaminopyridine (DMAP) as the base. Removal of the Boc in amino acids can be accomplished with strong acids such as trifluoroacetic acid neat or in dichloromethane or with HCl in methanol. A complication may be the tendency of the t-butyl cation intermediate to alkylate other nucleophiles; scavengers such as anisole or thioanisole may be used. Selective cleavage of the N-Boc group in the presence of other protecting groups is possible when using AlCl3. Reaction with trimethylsilyl iodide in acetonitrile followed by methanol is a mild and versatile method of deprotecting Boc-protected amines. The use of triethylsilane as a carbocation scavenger in the presence of trifluoroacetic acid in dichloromethane has been shown to lead to increased yields, decreased reaction times, simple work-up and improved selectivity for the deprotection of t-butyl ester and t-butoxycarbonyl sites in protected amino-acids and peptides in the presence of other acid-sensitive protecting groups such as the benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, O- and S-benzyl and t-butylthio groups.

Sources: en.wikipedia.org

Frequently asked questions